Indivior PLC - Chesterfield, Virginia-headquartered pharmaceutical maker - Reconfirms financial guidance for 2024 ahead of analyst 'teach-in' event in New York. Indivior also on Thursday is asking shareholders to approve moving its primary listing to New York from London.

Indivior expects net revenue between USD1.24 billion and USD1.33 billion in 2024, at least 13% higher than USD1.09 billion reported for 2023. Adjusted gross margin is seen in the low to mid-80s range. Expects adjusted operating profit between USD330 million and USD380 million, up at least 23% from USD269 million in 2023. Research & development costs are set to increase at least 13% to between USD120 million and USD130 million from USD106 million in 2023.

Current stock price: 1,369.50 pence each, up 3.4% on Thursday afternoon in London

12-month change: down 6.8%

By Tom Budszus, Alliance News slot editor

Comments and questions to

Copyright 2024 Alliance News Ltd. All Rights Reserved.